What is fluoxetine, including its indications, typical adult dosing, contraindications, and common adverse effects?

Fluoxetine: Comprehensive Clinical Overview

What Fluoxetine Is

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that potently and specifically blocks presynaptic serotonin reuptake with negligible effects on norepinephrine or other neurotransmitters, and minimal binding to neurotransmitter receptors. 1, 2, 3

• Fluoxetine was the first widely available SSRI and transformed psychiatric treatment by offering efficacy comparable to tricyclic antidepressants without their anticholinergic, cardiovascular, and sedative toxicity 1, 4
• The drug is metabolized to an active metabolite, norfluoxetine, which also selectively inhibits serotonin reuptake 2, 4
• Both fluoxetine and norfluoxetine have exceptionally long elimination half-lives (4 days and 7 days respectively after chronic dosing), which essentially eliminates withdrawal phenomena but delays onset and offset of effects 2, 5, 4

FDA-Approved Indications

Fluoxetine holds the broadest FDA approval among antidepressants and is the only agent approved for pediatric depression (ages ≥8 years). 1

Approved Uses:

• Major depressive disorder (including pediatric patients ≥8 years) 1
• Obsessive-compulsive disorder 1
• Panic disorder 1, 6
• Bulimia nervosa 1, 6
• Premenstrual dysphoric disorder 1, 6
• Bipolar depression (in combination with olanzapine) 1, 6

Adult Dosing

Standard Depression/Anxiety Dosing:

• Initial dose: 20 mg once daily 2, 5
• Therapeutic range: 20–40 mg daily for most indications 2
• Maximum approved dose: 80 mg daily 2, 5

OCD-Specific Dosing:

• Higher doses (60–80 mg daily) demonstrate superior efficacy for OCD compared to lower doses 1, 6
• A 2010 meta-analysis confirmed that fluoxetine 60–80 mg is more effective than standard dosing for obsessive-compulsive disorder 1

Dosing Considerations:

• Once-daily administration is standard due to the long half-life 2, 4
• Steady-state plasma concentrations are maintained easily during long-term treatment 4
• The long half-life means dose adjustments should be made at intervals of several weeks 5

Critical Contraindications

Absolute Contraindications:

• Concurrent use with monoamine oxidase inhibitors (MAOIs) due to serotonin syndrome risk 1
• Known hypersensitivity to fluoxetine 5

Relative Contraindications and Cautions:

• Patients with marked agitation: Fluoxetine is classified as "activating" and may worsen agitation, anxiety, or insomnia initially 1, 6
• CYP2D6 poor metabolizers: These patients have 3.9-fold higher drug exposure at 20 mg and 11.5-fold higher exposure at 60 mg, substantially increasing risk of QT prolongation, arrhythmias, and serotonin syndrome 1, 6
• Patients requiring tamoxifen: Fluoxetine strongly inhibits CYP2D6 and reduces conversion of tamoxifen to its active metabolite endoxifen, potentially compromising cancer treatment 1, 6

Common Adverse Effects

Most Frequent Side Effects (dose-related):

• Nausea (most common reason for discontinuation in trials) 1, 2, 5, 4
• Anxiety and nervousness 2, 5, 4
• Insomnia 1, 2, 5, 4
• Anorexia and weight loss (moderate and transient) 2, 7
• Diarrhea 1, 2
• Headache 1, 2, 5

Severe Adverse Events:

Sexual Dysfunction:

• Bupropion has significantly lower rates of sexual adverse events than fluoxetine 1
• Absolute rates of sexual dysfunction are likely underreported in clinical trials 1

Suicidality:

• All SSRIs including fluoxetine carry FDA black box warnings for treatment-emergent suicidality, particularly in adolescents and young adults under age 24 1, 6
• Meta-analyses show SSRIs increase risk of nonfatal suicide attempts (odds ratio 1.57–2.25) though not completed suicide 1
• Close monitoring is essential during the first 1–2 weeks after initiation or dose changes 6

Cardiovascular:

• Fluoxetine lacks the cardiovascular toxicity of tricyclic antidepressants and is safer in overdose 7, 4
• However, QT prolongation risk increases in CYP2D6 poor metabolizers or with CYP2D6 inhibitors 1, 6

Drug Interactions

Fluoxetine is a potent inhibitor of CYP2D6, CYP2C, and CYP3A4 enzymes, creating significant drug interaction potential. 1, 5, 7

Critical Interactions:

• Tamoxifen: Fluoxetine reduces conversion to active endoxifen, potentially compromising breast cancer treatment 1, 6
• Codeine and tramadol: Reduced analgesic efficacy due to CYP2D6 inhibition 6
• Other serotonergic agents: Increased serotonin syndrome risk with triptans, other antidepressants, St. John's wort 1, 6
• Fluoxetine converts approximately 43% of normal CYP2D6 metabolizers to poor metabolizer phenotype with chronic use through auto-inhibition 1, 6

Treatment Duration

• Continue for 4–9 months minimum after satisfactory response for first-episode depression 1, 6
• Consider ≥1 year duration for recurrent episodes 1, 6
• Meta-analysis of 31 trials demonstrates that continuation therapy significantly reduces relapse risk 6

Comparative Efficacy

All second-generation antidepressants (SSRIs and SNRIs) show no clinically significant differences in efficacy for major depression, with approximately 62% response rates and 46% remission rates after 6–12 weeks. 1, 6

• 38% of patients do not achieve treatment response during 6–12 weeks, and 54% do not achieve remission 1, 6
• Mirtazapine has statistically faster onset of action than fluoxetine, though response rates equalize after 4 weeks 1, 6
• Limited evidence suggests venlafaxine may have better response rates than fluoxetine specifically for depression with prominent anxiety symptoms 6

Pharmacogenetic Considerations

CYP2D6 genetic testing should be considered before prescribing fluoxetine, particularly at higher doses. 1, 6

• CYP2D6 poor metabolizers require substantially lower doses to avoid toxicity 1, 6
• A case report documented fatal metabolic toxicity in a 9-year-old CYP2D6 poor metabolizer treated with high-dose fluoxetine (80–100 mg/day), resulting in seizures, cardiac arrest, and death 6
• FDA safety labeling changes recommend caution in CYP2D6 poor metabolizers and those on CYP2D6 inhibitors 6

Common Pitfalls to Avoid

• Do not prescribe fluoxetine to highly agitated patients—its activating properties may worsen symptoms initially 1, 6
• Do not combine with MAOIs—allow at least 2 weeks washout when switching 6
• Do not use in patients requiring tamoxifen—choose sertraline or escitalopram instead 1, 6
• Do not escalate doses rapidly—the long half-life requires intervals of several weeks between adjustments 5
• Do not discontinue abruptly—although fluoxetine has the lowest discontinuation syndrome risk among SSRIs due to its long half-life, gradual tapering is still recommended 6